NEW
YORK, Dec. 5, 2024 /PRNewswire/ -- The Gross Law
Firm issues the following notice to shareholders of Edwards
Lifesciences Corporation (NYSE: EW).
Shareholders who purchased shares of EW during the class period
listed are encouraged to contact the firm regarding possible lead
plaintiff appointment. Appointment as lead plaintiff is not
required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/edwards-lifesciences-loss-submission-form/?id=114718&from=4
CLASS PERIOD: February 6,
2024 to July 24, 2024
ALLEGATIONS: According to the complaint, defendants
provided investors with material information concerning Edwards'
expected revenue for the fiscal year 2024, particularly as it
related to the growth of the Company's core product, Transcatheter
Aortic Valve Replacement ("TAVR"). Defendants' statements included,
among other things, strong commitment to the TAVR platform,
confidence in the Company's ability to capitalize on a subset of
untreated patients through scaling of its various patient
activation activities, and continued claims of significant demand
in allegedly lower-penetrated markets. On July 24, 2024, Edwards unveiled below-expectation
financial results for the second quarter of fiscal 2024 and, in
particular, slashed its revenue guidance for the TAVR platform for
the full fiscal year 2024. The Company attributed the TAVR setback
on the "continued growth and expansion of structural heart
therapies … [which] put pressure on hospital workflows." Investors
understood this to mean that developments in new procedures,
including defendant's own Transcatheter Mitral and Tricuspid
Therapies ("TMTT"), put significant strain on hospital structural
heart teams such that they were underutilizing TAVR, despite the
Company's continued claim of a significantly undertreated patient
population. Moreover, the Company announced three acquisitions
during the second quarter designed to embolden their treatments
alternative to TAVR, suggesting further that the company was aware
of the potential for the TAVR platform's decelerated growth.
Investors and analysts reacted immediately to Edwards' revelations.
The price of Edwards' common stock declined dramatically. From a
closing market price of $86.95 per
share on July 24, 2024, Edwards'
stock price fell to $59.70 per share
on July 25, 2024, a decline of about
31.34% in the span of just a single day.
DEADLINE: December 13, 2024
Shareholders should not delay in registering for this class action.
Register your information here:
https://securitiesclasslaw.com/securities/edwards-lifesciences-loss-submission-form/?id=114718&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a
shareholder who purchased shares of EW during the timeframe listed
above, you will be enrolled in a portfolio monitoring software to
provide you with status updates throughout the lifecycle of the
case. The deadline to seek to be a lead plaintiff is December 13, 2024. There is no cost or obligation
to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal business practices. The Gross Law
Firm is committed to ensuring that companies adhere to responsible
business practices and engage in good corporate citizenship. The
firm seeks recovery on behalf of investors who incurred losses when
false and/or misleading statements or the omission of material
information by a company lead to artificial inflation of the
company's stock. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original content to download
multimedia:https://www.prnewswire.com/news-releases/the-gross-law-firm-announces-the-filing-of-a-securities-class-action-on-behalf-of-edwards-lifesciences-corporationew-shareholders-302323093.html
SOURCE The Gross Law Firm